Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab

Keisuke Ojiro; Makoto Naganuma; Hirotoshi Ebinuma; Hiroyoshi Kunimoto; Shinichiro Tada; Haruhiko Ogata; Yasushi Iwao; Hidetsugu Saito; Toshifumi Hibi

doi:10.1007/s00535-008-2165-x

Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab

Keisuke Ojiro, Makoto Naganuma, Hirotoshi Ebinuma, Hiroyoshi Kunimoto, Shinichiro Tada, Haruhiko Ogata, Yasushi Iwao, Hidetsugu Saito, Toshifumi Hibi

Center for Endoscopy

Research output: Contribution to journal › Article › peer-review

81 Citations (Scopus)

Abstract

We encountered a case of reactivation of hepatitis B virus after administration of infliximab for Crohn's disease. The use of infliximab was considered because the patient displayed abdominal symptoms and perianal lesions. Transaminases were normal, and hepatitis B virus (HBV) DNA was undetectable before treatment, so no antiviral treatment was used, and infliximab and low-dose 6-mercaptopurine were administered. This treatment was effective, but liver dysfunction and reactivation of HBV were observed after the fourth injection of infliximab. This is the first report of Crohn's disease for which infliximab use was continued even after reactivation of HBV was observed. However, liver dysfunction was not improved by lamivudine. Antiviral treatment should be considered before administration of infliximab for patients with HBV.

Original language	English
Pages (from-to)	397-401
Number of pages	5
Journal	Journal of gastroenterology
Volume	43
Issue number	5
DOIs	https://doi.org/10.1007/s00535-008-2165-x
Publication status	Published - 2008 May

Keywords

Crohn's disease
HBV
Infliximab

ASJC Scopus subject areas

Gastroenterology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00535-008-2165-x

Cite this

@article{425c3425558440038a283a2f0391b17c,

title = "Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab",

abstract = "We encountered a case of reactivation of hepatitis B virus after administration of infliximab for Crohn's disease. The use of infliximab was considered because the patient displayed abdominal symptoms and perianal lesions. Transaminases were normal, and hepatitis B virus (HBV) DNA was undetectable before treatment, so no antiviral treatment was used, and infliximab and low-dose 6-mercaptopurine were administered. This treatment was effective, but liver dysfunction and reactivation of HBV were observed after the fourth injection of infliximab. This is the first report of Crohn's disease for which infliximab use was continued even after reactivation of HBV was observed. However, liver dysfunction was not improved by lamivudine. Antiviral treatment should be considered before administration of infliximab for patients with HBV.",

keywords = "Crohn's disease, HBV, Infliximab",

author = "Keisuke Ojiro and Makoto Naganuma and Hirotoshi Ebinuma and Hiroyoshi Kunimoto and Shinichiro Tada and Haruhiko Ogata and Yasushi Iwao and Hidetsugu Saito and Toshifumi Hibi",

year = "2008",

month = may,

doi = "10.1007/s00535-008-2165-x",

language = "English",

volume = "43",

pages = "397--401",

journal = "Journal of gastroenterology",

issn = "0944-1174",

publisher = "Springer Japan",

number = "5",

}

TY - JOUR

T1 - Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab

AU - Ojiro, Keisuke

AU - Naganuma, Makoto

AU - Ebinuma, Hirotoshi

AU - Kunimoto, Hiroyoshi

AU - Tada, Shinichiro

AU - Ogata, Haruhiko

AU - Iwao, Yasushi

AU - Saito, Hidetsugu

AU - Hibi, Toshifumi

PY - 2008/5

Y1 - 2008/5

N2 - We encountered a case of reactivation of hepatitis B virus after administration of infliximab for Crohn's disease. The use of infliximab was considered because the patient displayed abdominal symptoms and perianal lesions. Transaminases were normal, and hepatitis B virus (HBV) DNA was undetectable before treatment, so no antiviral treatment was used, and infliximab and low-dose 6-mercaptopurine were administered. This treatment was effective, but liver dysfunction and reactivation of HBV were observed after the fourth injection of infliximab. This is the first report of Crohn's disease for which infliximab use was continued even after reactivation of HBV was observed. However, liver dysfunction was not improved by lamivudine. Antiviral treatment should be considered before administration of infliximab for patients with HBV.

AB - We encountered a case of reactivation of hepatitis B virus after administration of infliximab for Crohn's disease. The use of infliximab was considered because the patient displayed abdominal symptoms and perianal lesions. Transaminases were normal, and hepatitis B virus (HBV) DNA was undetectable before treatment, so no antiviral treatment was used, and infliximab and low-dose 6-mercaptopurine were administered. This treatment was effective, but liver dysfunction and reactivation of HBV were observed after the fourth injection of infliximab. This is the first report of Crohn's disease for which infliximab use was continued even after reactivation of HBV was observed. However, liver dysfunction was not improved by lamivudine. Antiviral treatment should be considered before administration of infliximab for patients with HBV.

KW - Crohn's disease

KW - HBV

KW - Infliximab

UR - http://www.scopus.com/inward/record.url?scp=46949085913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46949085913&partnerID=8YFLogxK

U2 - 10.1007/s00535-008-2165-x

DO - 10.1007/s00535-008-2165-x

M3 - Article

C2 - 18592158

AN - SCOPUS:46949085913

SN - 0944-1174

VL - 43

SP - 397

EP - 401

JO - Journal of gastroenterology

JF - Journal of gastroenterology

IS - 5

ER -

Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this